

# Shoya Iwanami

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7886689/shoya-iwanami-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18  
papers

174  
citations

8  
h-index

13  
g-index

27  
ext. papers

385  
ext. citations

5.4  
avg, IF

2.69  
L-index

#	Paper	IF	Citations
18	Multidrug treatment with nelfinavir and cepharanthine against COVID-19		35
17	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. <i>IScience</i> , <b>2021</b> , 24, 102367	6.1	34
16	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. <i>PLoS Biology</i> , <b>2021</b> , 19, e3001128 <sup>9.7</sup>		25
15	Modelling SARS-CoV-2 Dynamics: Implications for Therapy		15
14	Estimation of the incubation period of COVID-19 using viral load data. <i>Epidemics</i> , <b>2021</b> , 35, 100454	5.1	12
13	A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture. <i>Theoretical Biology and Medical Modelling</i> , <b>2017</b> , 14, 9	2.3	11
12	Inferring Timing of Infection Using Within-host SARS-CoV-2 Infection Dynamics Model: Are Imported Cases Truly Imported?		8
11	Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003660	11.6	8
10	Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 651403	5.7	6
9	Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment		5
8	Revisiting the guidelines for ending isolation for COVID-19 patients. <i>ELife</i> , <b>2021</b> , 10,	8.9	4
7	Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma. <i>PLoS Biology</i> , <b>2020</b> , 18, e3000562	9.7	2
6	Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. <i>Life Science Alliance</i> , <b>2021</b> , 4,	5.8	2
5	Quantitative Immunology by Data Analysis Using Mathematical Models <b>2019</b> , 984-992		1
4	Revealing uninfected and infected target cell dynamics from peripheral blood data in highly and less pathogenic simian/human immunodeficiency virus infected Rhesus macaque. <i>Journal of Theoretical Biology</i> , <b>2019</b> , 479, 29-36	2.3	1
3	Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. <i>Journal of the Royal Society Interface</i> , <b>2021</b> , 18, 20200947	4.1	1
2	Antithetic effect of interferon- $\beta$ on cell-free and cell-to-cell HIV-1 infection.. <i>PLoS Computational Biology</i> , <b>2022</b> , 18, e1010053	5	0

- 1 Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials. *Translational and Regulatory Sciences*, **2021**, 3, 85-88 0.3